This study explores how inflammation and cholesterol levels predict cardiovascular events among 13,970 statin-intolerant patients in the CLEAR Outcomes trial. Findings suggest residual inflammatory risk may be a stronger predictor than residual cholesterol risk for future events. The research analyz

0 views • 17 slides

The REPRIEVE trial focuses on developing a cardiovascular disease prevention strategy for individuals living with HIV. It addresses the increased risk of CVD in this population, even with good viral suppression. The study evaluates the use of pitavastatin, a statin with anti-inflammatory properties,

1 views • 33 slides

This study led by Dr. Steven E. Nissen explores a novel Web Application aimed at helping consumers qualify for nonprescription access to rosuvastatin (5 mg) based on their ASCVD risk scores. The application features innovative eligibility criteria and outcomes, filling a gap in providing statin trea

0 views • 20 slides

This guideline outlines the management of blood cholesterol in high-risk groups according to the 2018 ACC/AHA recommendations. It discusses the overall approach, different statin management groups, justification for statin use in high-risk populations, high and moderate-intensity statin therapy, and

1 views • 14 slides

Statin intolerance is the inability to tolerate at least two statins, with symptoms like muscle aches. Despite the benefits of statins in reducing cardiovascular risk, some patients experience side effects leading to intolerance. Understanding the definition, prevalence, and management of statin int

0 views • 43 slides

The Affinity Care Lipid Pathway outlines a systematic approach to assessing lipid/cholesterol blood results in individuals over 16 years old. It includes guidelines for managing cholesterol levels, assessing familial hypercholesterolemia, and determining appropriate medication options based on indiv

0 views • 5 slides

Lipoprotein(a) levels play a crucial role in cardiovascular disease risk assessment, especially in patients undergoing statin therapy. This individual patient-data meta-analysis from the Lancet explores the predictive value of lipoprotein(a) levels in 29,069 patients across seven landmark statin tri

0 views • 10 slides